Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Rare Diseases

Melanoma

Melanoma, Cutaneous Malignant

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Opdualag

Anna Spreafico, MD

Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to anti-PD-1 inhibition in patients with detectable circulating tumor deoxyribonucleic acid (ctDNA) following definitive surgery for high risk melanoma. Patients will be allocated to either Arm A or Arm B via the process of randomization. The randomization process will be stratified according to stage (Stage 2A/2B/3A/3B/3C/3D or 4), to ensure absolute balance between stage groups. The investigators are choosing only 1 stratification factor, disease stage, as the investigators consider stage being the most significant prognosticating variable. Each stage represents a biologically distinct entity with varying recurrence rate outcomes. Block randomization will be performed to ensure equal sample sizes in the combination and monotherapy arms. At least 54 patients will be included in the randomized part of the study. The investigators are expecting approximately 20% of the patients to have detectable ctDNA after definite surgery. Therefore, approximately 270 patients are expected to be enrolled and tested for ctDNA in the entire study.

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High Risk Melanoma

patient reported outcomes using 'European Organization for Research and Treatment of Cancer' (EORTC) 'Quality of Life Questionnaire' (QLQ-C30) will be investigated. The score ranges from 1 to 4, with 1 being the worst outcome and 4 being the best. Mean score of individual item numbers of interest will be analyzed with descriptive and mixed effect model methods.

University Health Network, Toronto

Relatlimab

Nivolumab + Relatlimab

rHuPH20

BMS Study Connect Contact Center www.BMSStudyConnect.com

First line of the email MUST contain the NCT# and Site #.

Miguel Gonzalez Velez, Site 0125

Site 0189

Inderjit Mehmi, Site 0098

Warren Chow, Site 0093

Sunil Reddy, Site 0123

Ryan Weight, Site 0113

Roxana Dronca, Site 0114

Petr Hausner, Site 0146

Svetomir Markovic, Site 0071

Ralph Hauke, Site 0013

Brian Gastman, Site 0169

Melissa Wilson, Site 0139

Rino Seedor, Site 0124

Caroline Nebhan, Site 0122

Sekwon Jang, Site 0115

Site 0023

Site 0067

Site 0070

Site 0133

Site 0145

Site 0160

Site 0057

Site 0020

Karen Briscoe, Site 0050

Matteo Carlino, Site 0175

Georgia Ritchie, Site 0172

David Palmieri, Site 0118

Site 0184

Matteo Carlino, Site 0033

Georgina Long, Site 0055

Jeremy Long, Site 0090

Samuel Harris, Site 0008

Site 0059

Damien Kee, Site 0154

Andrew Haydon, Site 0030

Quan Tran, Site 0109

Adnan Khattak, Site 0161

Peter Lau, Site 0106

Site 0027

Peter Koelblinger, Site 0029

Christine Hafner, Site 0168

Christoph Hoeller, Site 0037

Jean-Francois Baurain, Site 0072

Christophe Lonchay, Site 0078

Andree Rorive, Site 0016

Site 0177

Alberto Julius Alves Wainstein, Site 0107

Fabio Franke, Site 0025

Juliana Menezes, Site 0002

Sergio De Azevedo, Site 0031

Fernanda Damian, Site 0058

Site 0179

Site 0182

Fernanda Hassan, Site 0009

Joao Daniel Cardoso Guedes, Site 0018

Sandro Reichow, Site 0159

Site 0180

Andreia De Melo, Site 0110

Site 0130

Jose Monzon, Site 0141

Elaine Mcwhirter, Site 0121

Xinni Song, Site 0096

Teresa Petrella, Site 0116

Felix Couture, Site 0103

Patricio Yanez Weber, Site 0143

Site 0178

Carlos Rojas Garcia, Site 0140

Sebastian Mondaca, Site 0144

Christian Caglevic, Site 0017

Site 0010

Paola Celedon, Site 0074

Marcelo Garrido, Site 0119

Alenjandro Andres Acevedo Gaete, Site 0028

Site 0176

Ivana Krajsova, Site 0083

Jindrich Kopecky, Site 0094

Bohuslav Melichar, Site 0091

Yvetta Vantuchova, Site 0082

Monika Arenbergerova, Site 0095

Micaela Hernberg, Site 0164

Tanja Skytta, Site 0167

Kalle Mattila, Site 0162

Cecile Pages Laurent, Site 0108

Celeste Lebbe, Site 0034

Site 0127

Laurent MORTIER, Site 0111

Gaelle Quereux, Site 0063

Caroline Robert, Site 0061

Jean-Philippe Arnault, Site 0007

Bristol-Myers Squibb

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma	NCT06319196	Cutaneous Melan... Melanoma Stage ... Mucosal Melanom...	Opdualag Nivolumab	18 Years -	University Health Network, Toronto
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma	NCT06319196	Cutaneous Melan... Melanoma Stage ... Mucosal Melanom...	Opdualag Nivolumab	18 Years -	University Health Network, Toronto
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma	NCT05625399	Melanoma	Nivolumab + Rel... rHuPH20	12 Years -	Bristol-Myers Squibb

Spots Global Cancer Trial Database for opdualag

Every month we try and update this database with for opdualag cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for opdualag

Every month we try and update this database with for opdualag cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for opdualag cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.